Premium
Antibody microarray profiling of human prostate cancer sera: Antibody screening and identification of potential biomarkers
Author(s) -
Miller Jeremy C.,
Zhou Heping,
Kwekel Joshua,
Cavallo Robert,
Burke Jocelyn,
Butler E. Brian,
Teh Bin S.,
Haab Brian B.
Publication year - 2003
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.200390009
Subject(s) - antibody microarray , protein microarray , prostate cancer , dna microarray , antibody , microarray , protein array analysis , tissue microarray , proteomics , microbiology and biotechnology , chemistry , cancer , biology , immunology , biochemistry , gene expression , genetics , gene
We developed a practical strategy for serum protein profiling using antibody microarrays and applied the method to the identification of potential biomarkers in prostate cancer serum. Protein abundances from 33 prostate cancer and 20 control serum samples were compared to abundances from a common reference pool using a two‐color fluorescence assay. Robotically spotted microarrays containing 184 unique antibodies were prepared on two different substrates: polyacrylamide based hydrogels on glass and poly‐1‐lysine coated glass with a photoreactive cross‐linking layer. The hydrogel substrate yielded an average six‐fold higher signal‐to‐noise ratio than the other substrate, and detection of protein binding was possible from a greater number of antibodies using the hydrogels. A statistical filter based on the correlation of data from “reverse‐labeled” experiment sets accurately predicted the agreement between the microarray measurements and enzyme‐linked immunosorbent assay measurements, showing that this parameter can serve to screen for antibodies that are functional on microarrays. Having defined a set of reliable microarray measurements, we identified five proteins (von Willebrand Factor, immunoglobulinM, Alpha1‐antichymotrypsin, Villin and immunoglobulinG) that had significantly different levels between the prostate cancer samples and the controls. These developments enable the immediate use of high‐density antibody and protein microarrays in biomarker discovery studies.